|
1
|
Bozec A, Lassalle S, Hofman V, Ilie M,
Santini J and Hofman P: The thyroid gland: A crossroad in
inflammation-induced carcinoma? An ongoing debate with new
therapeutic potential. Curr Med Chem. 17:3449–3461. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Muzza M, Degl'Innocenti D, Colombo C,
Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG
and Fugazzola L: The tight relationship between papillary thyroid
cancer, autoimmunity and inflammation: Clinical and molecular
studies. Clin Endocrinol (Oxf). 72:702–708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Babli S, Payne RJ, Mitmaker E and Rivera
J: Effects of chronic lymphocytic thyroiditis on the
clinicopathological features of papillary thyroid cancer. Eur
Thyroid J. 7:95–101. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ott RA, Calandra DB, McCall A, Shah KH,
Lawrence AM and Paloyan E: The incidence of thyroid carcinoma in
patients with Hashimoto's thyroiditis and solitary cold nodules.
Surgery. 98:1202–1206. 1985.PubMed/NCBI
|
|
5
|
Schäffer A, Palitzsch KD, Seiffarth C,
Hohne HM, Riedhammer FJ, Hofstädter F, Schölmerich J and Rüschoff
J: Coexistent thyroiditis is associated with lower tumour stage in
thyroid carcinoma. Eur J Clin Invest. 28:838–844. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loh KCH, Greenspan FS, Dong F, Miller TR
and Yeo PPB: Influence of lymphocytic thyroiditis on the prognostic
outcome of patients with papillary thyroid carcinoma. J Clin
Endocrinol Metab. 84:458–463. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shih ML, Lee JA, Hsieh CB, Yu JC, Liu HD,
Kebebew E, Clark OH and Duh QY: Thyroidectomy for Hashimoto's
thyroiditis: Complications and associated cancers. Thyroid.
18:729–734. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fiore E, Rago T, Latrofa F, Provenzale MA,
Piaggi P, Delitala A, Scutari M, Basolo F, Di Coscio G, Grasso L,
et al: Hashimoto's thyroiditis is associated with papillary thyroid
carcinoma: Role of TSH and of treatment with L-thyroxine. Endocr
Relat Cancer. 18:429–437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vaccarella S, Franceschi S, Bray F, Wild
CP, Plummer M and Dal Maso L: Worldwide thyroid-cancer epidemic?
The increasing impact of overdiagnosis. N Engl J Med. 7:614–617.
2016. View Article : Google Scholar
|
|
10
|
Antonaci A, Consorti F, Mardente S and
Giovannone G: Clinical and biological relationship between chronic
lymphocytic thyroiditis and papillary thyroid carcinoma. Oncol Res.
17:495–503. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prescott SM and Fitzpatrick FA:
Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta.
1470:M69–M78. 2000.PubMed/NCBI
|
|
12
|
Cornetta A, Russell JP, Cunnane M, Keane
WM and Rothstein JL: Cyclooxygenase-2 expression in human thyroid
carcinoma and Hashimoto's thyroiditis. Laryngoscope. 112:238–242.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmidt JA, Allen NE, Almquist M,
Franceschi S, Rinaldi S, Tipper SJ, Tsilidis KK, Weiderpass E,
Overvad K, Tjønneland A, et al: Insulin-like growth factor-i and
risk of differentiated thyroid carcinoma in the European
prospective investigation into cancer and nutrition. Cancer
Epidemiol Biomarkers Prev. 23:976–985. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu J, Mai W, Ciu Y and Kong L: Key genes
and pathways predicted in papillary thyroid carcinoma based on
bioinformatics analysis. J Endocrinol Invest. 39:1285–1293. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eldien MMS, Abdou AG, Rageh T, Abdelrazek
E and Elkholy E: Immunohistochemical expression of ER-α and PR in
papillary thyroid carcinoma. Ecancermedicalscience. 11:7482017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM classification of malignant tumours8th. Oxford:
Wiley Blackwell. ISBN 9781119263579. 2017
|
|
17
|
Brtko J, Sejnová D, Ondková S and Macejová
D: Malignant Triton tumour exhibits a complete expression pattern
of nuclear retinoid and rexinoid receptor subtypes. Gen Physiol
Biophys. 28:425–427. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Macejová D, Galbavý S, Podoba J, Bialešová
L and Brtko J: mRNA expression pattern of retinoic acid and
retinoid X nuclear receptor subtypes in human thyroid papillary
carcinoma. Oncol Rep. 30:2371–2378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Franceschi S, Boyle P, Maisonneuve P, La
Vecchia C, Burt AD, Kerr DJ and MacFarlane GJ: The epidemiology of
thyroid carcinoma. Crit Rev Oncog. 4:25–52. 1993.PubMed/NCBI
|
|
20
|
Lai X, Xia Y, Zhang B, Li J and Jiang Y: A
meta-analysis of Hashimoto's thyroiditis and papillary thyroid
carcinoma risk. Oncotarget. 8:62414–62424. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paolieri F, Salmaso C, Battifora M,
Montagna P, Pesce G, Bagnasco M, Richiusa P, Galluzzo A and
Giordano C: Possible pathogenetic relevance of interleukin-1 beta
in ‘destructive’ organ-specific autoimmune disease (Hashimoto's
thyroiditis). Ann N Y Acad Sci. 876:221–228. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu L and Gudas LJ: Retinoic acid induces
expression of the interleukin-1beta gene in cultured normal human
mammary epithelial cells and in human breast carcinoma lines. J
Cell Physiol. 193:244–252. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ciampolillo A, De Tullio C and Giorgino F:
The IGF-I/IGF-I receptor pathway: Implications in the
pathophysiology of thyroid cancer. Curr Med Chem. 12:2881–2891.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Surmacz E and Bartucci M: Role of estrogen
receptor alpha in modulating IGF-I receptor signaling and function
in breast cancer. J Exp Clin Cancer Res. 23:385–394.
2004.PubMed/NCBI
|
|
25
|
Garcia-Solis P and Aceves C: 5′Deiodinase
in two breast cancer cell lines: Effect of triiodothyronine,
isoproterenol and retinoids. Mol Cell Endocrinol. 201:25–31. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dhiman VK, Bolt MJ and White KP: Nuclear
receptors in cancer-uncovering new and evolving roles through
genomic analysis. Nat Rev Genet. 19:160–174. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim WG and Cheng SY: Thyroid hormone
receptors and cancer. Biochim Biophys Acta. 1830:3928–3936. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nugroho J and Schweiger B: Isotretinoin as
a possible environmental trigger to autoimmunity in genetically
susceptible patients. Case Rep Pediatr. 2017:42076562017.PubMed/NCBI
|
|
29
|
Schmutzler C, Brtko J, Winzer R, Jakobs
TC, Meissner-Weigl J, Simon D, Goretzki PE and Köhrle J: Functional
retinoid and thyroid hormone receptors in human thyroid-carcinoma
cell lines and tissues. Int J Cancer. 76:368–376. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hoftijzer HC, Liu YY, Morreau H, van Wezel
T, Pereira AM, Corssmit EP, Romijn JA and Smit JW: Retinoic acid
receptor and retinoid X receptor subtype expression for the
differential diagnosis of thyroid neoplasms. Eur J Endocrinol.
160:631–638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haugen BR, Larson LL, Pugazhenthi U, Hays
WR, Klopper JP, Kramer CA and Sharma V: Retinoic acid and retinoid
X receptors are differentially expressed in thyroid cancer and
thyroid carcinoma cell lines and predict response to treatment with
retinoids. J Clin Endocrinol Metab. 89:272–280. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim D: The role of vitamin D in thyroid
diseases. Int J Mol Sci. 18(pii): E19492017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Casula S and Bianco AC: Thyroid hormone
deiodinases and cancer. Front Endocrinol (Lausanne). 3:742012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y,
Dong J, Chen F, Wang X and Shen H: Phenotypes and genotypes of
insulin-like growth factor 1, IGF-binding protein-3 and cancer
risk: Evidence from 96 studies. Eur J Hum Genet. 17:1668–1675.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin K, He S, He L, Chen J, Cheng X, Zhang
G and Zhu B: Complement component 3 is a prognostic factor of
non-small cell lung cancer. Mol Med Rep. 10:811–817. 2014.
View Article : Google Scholar : PubMed/NCBI
|
